Ronald Brus resigns from the Galapagos Board
Galapagos NV announced that Dr Ronald Brus has resigned from the Board of Directors.
Ronald Brus is President and Chief Executive Officer of Crucell. Dr Brus was a member of the Galapagos Board of Directors from 2000 until Galapagos' IPO in May 2005 and later rejoined the Board in April 2010. In February 2011, Crucell was acquired by Johnson & Johnson. Corporate policies at Johnson & Johnson stipulate that managers cannot serve as a member of any Board of Directors, and therefore Dr Brus resigned from Galapagos' Board effective 25 May 2011.
"We thank Ronald again for his contribution as a Board member," said Onno van de Stolpe, CEO of Galapagos. "Ronald has been involved with Galapagos from the start, and we have benefited from his strategic insights and experience as a successful biotech CEO. We wish him the best within Johnson & Johnson."
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Graffinity and Amgen enter into drug discovery research agreement
Heptares moves to Welwyn BioPark and plans further expansion
Horizon and Boehringer Ingelheim enter oncology research service collaboration

Optical generation of ultrasound via photoacoustic effect
